Health In Tech, Inc.
HITDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
MCS-2 15 mg/day
Lower Urinary Tract Symptoms
MCS-2
Lower Urinary Tract Symptoms
MCS®
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MCS-2 15 mg/day | Phase 3 | Lower Urinary Tract Symptoms | - | - |
MCS-2 | Phase 3 | Lower Urinary Tract Symptoms | - | - |
MCS® | Phase 2 | Prostate Cancer | - | - |
Frequently asked questions
What is in Health In Tech, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Health In Tech, Inc.'s (HIT) pipeline across Phase 3, Phase 2. Its lead program is MCS-2 15 mg/day (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Health In Tech, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Health In Tech, Inc. (HIT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HIT biotech catalysts?→
Add HIT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Health In Tech, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.